Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment

INTRODUCTION: Previous drug survival studies of dupilumab in atopic dermatitis (AD) show that many patients continue treatment through 1 year, suggesting that patients experience clinically relevant benefits with long-term treatment. METHODS: This post hoc analysis included data through week 100 fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April, Blauvelt, Andrew, Simpson, Eric L., Smith, Catherine H., Herranz, Pedro, Kataoka, Yoko, Seo, Seong Jun, Ferrucci, Silvia M., Chao, Jingdong, Chen, Zhen, Rossi, Ana B., Shumel, Brad, Tomondy, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776941/
https://www.ncbi.nlm.nih.gov/pubmed/34897582
http://dx.doi.org/10.1007/s13555-021-00643-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776941/
https://www.ncbi.nlm.nih.gov/pubmed/34897582
http://dx.doi.org/10.1007/s13555-021-00643-4

Ejemplares similares